Insulet (NASDAQ:PODD) Given New $170.00 Price Target at Citigroup

Insulet (NASDAQ:PODD) had its price target upped by Citigroup from $150.00 to $170.00 in a report issued on Thursday,Benzinga reports. Citigroup currently has a neutral rating on the medical instruments supplier’s stock.

PODD has been the subject of several other reports. Barclays upgraded shares of Insulet to a “hold” rating in a research report on Wednesday, October 7th. Royal Bank Of Canada upped their target price on Insulet from $160.00 to $180.00 and gave the company an “outperform” rating in a report on Thursday. TD Cowen reissued a “hold” rating on shares of Insulet in a research report on Wednesday. BTIG Research cut shares of Insulet from a “buy” rating to a “neutral” rating in a research report on Thursday, August 6th. Finally, Benchmark cut their price target on shares of Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Thirteen equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Insulet has a consensus rating of “Hold” and an average price target of $192.36.

Insulet Stock Performance

Shares of Insulet stock opened at $156.12 on Thursday. The company’s 50 day moving average price is $141.91 and its two-hundred day moving average price is $177.34. The firm has a market capitalization of $10.83 billion, a P/E ratio of 25.43, a P/E/G ratio of 1.25 and a beta of 1.06. Insulet has a fifty-two week low of $126.40 and a fifty-two week high of $354.88. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.51 and a quick ratio of 1.83.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.59 by $0.40. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The company had revenue of $842.00 million for the quarter, compared to the consensus estimate of $832.63 million. During the same quarter last year, the business posted $1.24 EPS. Insulet’s revenue for the quarter was up 19.2% on a year-over-year basis. On average, equities analysts forecast that Insulet will post 6.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Elevation Wealth Partners LLC lifted its position in Insulet by 115.6% in the 3rd quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 104 shares in the last quarter. Activest Wealth Management grew its holdings in Insulet by 186.3% during the third quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 149 shares in the last quarter. WPG Advisers LLC grew its holdings in Insulet by 169.3% during the third quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 171 shares in the last quarter. State of Wyoming grew its stake in shares of Insulet by 34.6% in the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock worth $60,000 after acquiring an additional 73 shares in the last quarter. Finally, Continuum Advisory LLC bought a new stake in shares of Insulet in the 2nd quarter worth $46,000.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 adjusted EPS of $1.99, above the $1.59 consensus, while revenue rose 19.2% year over year to $842 million and also topped estimates. The company announced a $1 billion share-repurchase program and updated its 2026 outlook. Insulet Q3 earnings and revenue beat
• Positive Sentiment: Several analysts lifted their price targets after the results. Bernstein raised its target to $200 and kept an outperform rating; RBC raised its target to $180 and also maintained outperform, while Canaccord reiterated Buy at $179. RBC price-target update
• Neutral Sentiment: Other target increases came with cautious ratings: JPMorgan and Citi moved to $170, UBS to $171, and Wells Fargo to $172, while retaining neutral or equal-weight stances. RBC sees valuation as attractive but notes a more conservative 2027 outlook. RBC valuation and outlook commentary
• Negative Sentiment: Management cautioned that growth may slow in 2027 and that competitors could take some share from Omnipod. Those forward-looking concerns may be outweighing the strong quarter and contributing to the stock’s decline. CEO comments on growth and competition

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.